



SINPHAR PHARMACEUTICAL CO., LTD.

2026 Investor Conference

Vice President: Chih Hsiao Chen

September 16, 2026



吉國新藥股份有限公司 (台灣宜蘭)

吉輝天力(杭州)藥業有限公司 (大陸杭州)

和田天力沙生藥劑開發有限公司 (新疆和田)

吉力醫療器材生技股份有限公司 (台灣南投)

Disclaimer

- 本簡報是建立於本公司從各項來源所取得之資訊。有些訊可能受未來不確定性因素影響，致使與原先本公司對於未來前景的說明迥異。未來若有變更或調整時，請以公開資訊觀測站公告資訊為依據。
- 所涉產業為法規高度規範與高度專業領域，提醒投資人須審慎投資。
- This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made.
(<http://mops.twse.com.tw/mops/web/index>)
- The industries involved are highly regulated and highly specialized fields, and investors are reminded to invest prudently.

Contents



- 1. Operations Development**
- 2. Financial Reports**
- 3. Sustainable Development**



From Taiwan to the World

2000 Sinphar TPEx-listed
2002 Sinphar TWSE-listed
2014 SynCoreBio TPEx-listed

1977

Established Sinphar
Ilan, Taiwan
Generic drugs, functional food,
cosmetics

2002

Invested in Sinphar TianLi &
He-Tian Tianli
Hangzhou (CN), Xinjiang(CN)
Generic, TCM, natural products

2012

Merged ZuniMed
Biotech
Nantou, Taiwan
Medical devices

1997

Established CanCap
Vancouver, Canada
Clinical control for New Drug of North
America, raw material sourcing

2008


Co-found SynCoreBio
Ilan, Taiwan
New Drug Development



Group Resource Integration and Sharing

Sinphar & Tian-Li

Shared R&D
Achievements for Mutual
Benefit
Collaborative Patent
Strategy
(e.g., Launch of Four
Products with Health
Food Permits)



Sinphar & SynCore

Collaborative Pharmaceutical R&D
Enhancement of Pharmaceutical
Manufacturing
(e.g., Lyophilization Process)

Sinphar & ZuniMed

ISO15378
Class 100,000 Cleanroom
(e.g., Container Integration)

Comprehensive health promotion



Recovery

Drugs

New Product Registration in 2027: 4

Staying Healthy

Functional Supplements

New Product Released in 2026: 4

New Product Released in 2027: 5

Youthfulness

Medical Cosmetology Products

New Product Released in 2026: 6

New Product Released in 2027: 9



International Award Winning Product



杏輝®
蓉憶記®

AIE2
專利成分 延緩衰老

**趁年輕
存老本**



神經內科醫師
余金登



Sinphar 杏輝醫藥集團
SINPHAR GROUP

延緩衰老 ➡ 國家認證 ➡ 思緒清晰 ➡






維生素B1 Vitamin B1

維持心臟正常功能 Support Heart Health

抗疲勞 Anti-Fatigue



獨家抗疲勞功效 **3** 專利成分
3 Exclusive Anti-Fatigue Ingredients With Patents



5大專利 超強活力

5 Patents High Energy Levels

*經動物實驗證實，有助於延緩運動後疲勞發生及促進運動後疲勞消除

Animal studies have shown that it helps to delay post-exercise fatigue and promote the elimination of post-exercise fatigue.

Stay healthy, stay beautiful



Product Portfolio

2026–2027 Two Product Series and Benefits



Radiant Hydration Series

Launch in
2026

- 3% Tranexamic Acid Whitening Essence Cream** Evens Skin Tone
- Tripeptide Elastic Repairing Cream** Hydration & Elasticity
- Squalane Revitalizing Anti-aging Oil** Moisturizing & Barrier Support

Planned for
2027

- PDNR Brightening Repair Cream EX+ with 3% Tranexamic Acid** Brightening & Repair
- Hypoallergenic UV Sunscreen Lotion SPF50+★★★★** High SPF Protection & Hypoallergenic

EXO Micro-Essence Series

Launch in
2026

- EXO Micro-Essence Advanced Repair Mask** Soothing Hydration, Pore Tightening

Planned for
2027

- EXO Micro-Essence Cream** Firming Skin, Fine Line Smoothing
- EXO Revitalizing Scalp Serum** Scalp Nourishment, Hair Strengthening

Sinphar Health Park – Sharing Knowledge with the Public

1. In cooperation with the Yilan County Government, Sinphar has integrated Renshan Botanical Garden and Xinliao Waterfall into a route promoting healthy living.
2. Since the beginning of the year, more than 600 groups, comprising approximately 22,000 visitors, have visited the Health Park.
3. An expansion plan is underway to accommodate the expected over 40,000 visitors for 2027.
4. Plans are underway to expand the Health Park.



International Markets

Japan

- Product G, steady growth
- Product L, steady growth
- Product A, steady growth

Thailand

- Product C, launched in 2023, steady growth
- Product M, under registration, expected to be launched in 2027

Malaysia

- Product T, launched in 2020, steady growth
- Product K, launched in 2021, steady growth
- Product M, under registration, expected to be launched in 2027
- Product Y, under registration, expected to be launched in 2027

Vietnam

- Product G, expect to obtain license in 2025
- Product A, applied in 2023, expect to obtain license in 2026
- Product L, applied in 2023
- Product C, launched in 2023, steady growth

Indonesia

- Product B, launched in 2023, steady growth
- Product M, under registration, expected to be launched in 2027

Hong Kong

- Product Y, under registration, expected to be launched in 2027





Growth

New Product Launch in 2027

- Pharmaceutical products expected to obtain marketing authorization: 4
- New functional food products planned for launch: 5
- New cosmetic products planned for launch: 9



New Markets

- Co-develop and manufacture with Japanese pharmaceutical companies and expand ASEAN market
- Agent to Japanese products for domestic market
- API in-depth development plan (4 products obtained license in recent 2 years; 2 more in development)
- Establish domestic alliance
- Expand presence in domestic chain retail channels

Expanded Investment

- Automated smart GDP-compliant warehouse (including space reserved for future production facilities, with a planned building height of over 30 meters and a site area of nearly 3,967 m²)
- Health and Vitality Center
- Expansion of production capacity for multiple dosage forms
- Energy-saving and carbon-reduction equipment

SynCore Bio



- Actively seeking partnerships for independently developed new drug formulations (liposomal products)
- License-out to drive operational growth

Building on the fish-derived cellular research platform, SynCore has developed proprietary fish-derived extracellular vesicles. In February 2026, FECV-01 obtained its International Nomenclature of Cosmetic Ingredients (INCI) name, enabling its compliant use as a cosmetic ingredient. SynCore plan to collaborate with aesthetic medicine specialists to further evaluate the clinical efficacy and potential applications of FECV-01.

Natural Resources (Raw Materials/Extracts)



Memoregain®

TLCT Plus

天力再生®

管花肉苁蓉萃取物
(*Cistanche tubulosa* extract)



Lipucan®

天力速康®

茯苓三萜萃取物
(*Poria cocos triterpenoids*)



Prottygold®

杏补宜®

W80 核桃肽粉

W80 Walnut peptide powder

P99 豌豆肽粉

P99 Pea peptide powder

M85 绿豆肽粉

M85 Mung bean peptide powder


E98 鹰嘴豆肽粉

E98 Chickpea peptide powder

Organic certification



EU Ecocert, USDA Organic, China Organic Food Certification Center




Innovative Plant-Based Ingredients

Backed by Patented Technology and Scientific Research

W80 核桃肽粉


W80 Walnut peptide



1. On the market for seven years and successfully sold in seven Asian countries.
2. Used in more than 100 products

M85 绿豆肽粉


M85 Mung bean peptide



1. An innovative plant peptide designed to support liver health.
2. Potential for diverse product applications.

P99 豌豆肽粉


P99 Pea peptide



1. Active health and wellness is emerging as a new global health trend.
2. An ideal ingredient for post-exercise recovery and muscle health.

E98 鹰嘴豆肽粉

E98 Chickpea peptide powder



1. An emerging source of plant-based protein with strong market differentiation.
2. Free from GMO-related concerns and other associated risk factors.

RD research achievements



Walnut oil won the **ITQI and Monde Selection** awards in 2023



Walnut oligopeptide won 4 gold and 1 silver **international patent invention awards**



Walnut oligopeptide Awards (2024-2025):

- **HI&FI Health Ingredients Gold Extract Award**
- **Nutrition Intelligence - Application Pioneer Award**



19 **SCI papers**




163 **patents in 19** **countries**



The ingredient has been sold to **14** countries.

Revenue Overview for the Same Period in Recent Years

Unit : NTD in thousands



1. As of August 2026, cumulative sales revenue is NTD 2.29 billion, which is NTD 126 million more for the same period last year. (an increase of 5.83%)
2. Driven by changes in the product mix and production batch sizes, as well as improved manufacturing efficiency, the gross profit margin has increased year over year.

Cash Flow

	Sinphar Group H1 2026	Sinphar Group 2025	Sinphar Group H1 2025
Net Cash generated by operating activities	194,445	584,662	180,795
Net Cash used in investing activities	-133,402	-224,626	-98,109
Acquisition of property, plant and equipment	-72,114	-95,115	-41,969
Prepaid equipment	-75,953	-99,594	-34,301
Net Cash generated by financing activities	535,527	-576,026	-235,738
Cash and cash equivalents, end of the period	1,476,846	864,139	890,695

Continue to invest, and increase investment recently.

Ratio

	Sinphar Group H1 2026	Sinphar Group H1 2025
Debt Ratio (%)	45.6	43.4
Current Ratio (%)	204	207
Days Sales Outstanding	75	74
Days Inventory Outstanding	152	142
Pre-Tax Net Profit Margin (%)	11.52	11.78
Earnings per Share (EPS)	0.87	0.95

Dividend Year	2022	2023	2024	2025
Cash Dividend from Earnings (NTD/Share)	1	1	1	1
Stock Dividend from Capitalization of Earnings (NTD/Share)	-	0.8	0.5	0.6



Energy Conservation and Emissions Reduction

Energy Saving
Energy Intensity
Reduced by
12.38%
(2025 vs 2024)
(Gigajoules/revenue in millions NTD)

節能減碳行動說明	節電量 (單位kWh)	節能量 (單位GJ)	減碳量 (單位噸CO ₂ e)
空調系統暨低效率冰機改善計畫	710,000	2,556.00	336.5400
J棟物流倉夜間用電時段調整 冷氣機溫度	17,224	62.01	8.1642



▲B棟新冰水主機



▲I棟新冰水主機

Sinphar complies with the “Regulations on Setting Energy Conservation Objectives and Execution Plans for Energy Users” established by the Energy Administration, MOEA. The Company continues to implement various energy-saving measures and has set an annual electricity savings target of at least 1%.

Energy Conservation and Carbon Reduction

Carbon Reduction

Emission Intensity
(Note)

Reduced by 4.57%

(2025 vs 2024)

(Metric ton of Co₂e/revenue in millions NTD)

溫室氣體排放量分析表

溫室氣體排放量	2025年	2024年
範疇一 (tCO ₂ e)	2,000.2665	1,297.9381
範疇二 (tCO ₂ e)	8,662.8621	9,124.7407
範疇三 (tCO ₂ e)	2,752.8072	未盤查
總排放量 (tCO ₂ e)	13,416.1140	10,422.6788
排放密集度 (tCO ₂ e/百萬元營業額)	4.3753	3.644

Note: In accordance with the principle of significance, Scope 3 emissions from employee commuting, downstream transportation, and fuel- and energy-related activities were included this year. As a result, the basis for GHG emissions calculations differs from that of previous years. To facilitate year-on-year comparison, the 4.57% reduction stated above was calculated by excluding Scope 3 emissions from the 2025 GHG emissions data.

In 2025, Sinphar completed its GHG inventory and engaged an independent third-party verification body to conduct assurance and verification. The verification opinion on the Company's 2025 GHG emissions confirms compliance with the requirements of ISO 14064-1:2018, with no material misstatements identified. Category 1 (Scope 1) and Category 2 (Scope 2) emissions were verified at a reasonable level of assurance, while Category 3 and Category 4 (Scope 3) emissions were verified at a limited level of assurance.

Talent Management

1. Hard assets: Bronze prize winning TTQS approved vocational training center
2. Intangible assets: utilize Talent Management System (TMS) to track and learning and professional development
3. From January to August 2026, TMS recorded approximately 400 users per month on average and approximately 1,700 content views per month



職業訓練中心



Management Philosophy

Average Monthly Salary of Group Employees (NT\$ Thousands)



(*Includes employee salaries, labor and health insurance contributions, pension contributions, and other personnel expenses)



Long-Term Co-hosting of the Sinphar Yilan Marathon with the Yilan County Government



Continued Support for the Yilan County Dementia Care Services Association



Continued Support for the Kinmen Long-Distance Swimming Event



Ongoing Health Seminars Across Taiwan

Corporate Social Responsibility

Promoting Social Well-Being, Disease Prevention, Health Education, and Community Engagement

1. Host health forum, biotechnology camp. Create a platform to facilitate and cultivate the interaction of medical, academic, and biotechnology professionals
2. Continue to be a sponsor for Taiwan Breast Cancer Foundation, Spinal Cord Injury Foundation, Taiwan Yilan Association of Diabetes Supporters, Youngsun Education Foundation, and The KMU Pharmacy Alumni Foundation for Culture and Education
3. Donate to the National Health Research Institutes and the Taiwan Cancer Foundation to support new drug development and medical assistance
4. Co-found an “R&D Center for Age-related Macular Degeneration” with National Taiwan University Hospital, for early diagnosis and early detection of age-related macular degeneration
5. Sponsored in remote villages, free clinics by Luodong Boai Hospital and co-sponsored with Taipei Zhongxiao Rotary Club breast cancer screenings
6. Provide Oxaliplatin to the National Health Research Institutes to conduct an IIT trial for pancreatic cancer treatment research
7. Donate to Yilan County Dementia Care Service Association
8. A six-year financial aid program for students of the NTU School of Pharmacy, along with internship opportunities during winter and summer breaks
9. Provide internship for students from Kaohsiung Medical University, Taipei Medical University, National Defense Medical Center, China Medical University, Chia Nan University of Pharmacy & Science, National Ilan University, and National Dong Hwa University. Also provide scholarship for Kaohsiung Medical University and National Defense Medical Center
10. Donate a total of NTD 5 million to Kaohsiung Medical University over five years to recruit outstanding talent and support disadvantaged students

Corporate Social Responsibility

Supports Education and Sports


1. Co-hosted the Sinphar Yilan Marathon with the Yilan County Government, with the event soon entering its sixth edition
2. Sponsored the Yilan County Government in hosting the National Games, National High School Athletic Games, and National Indigenous Games
3. Provided long-term sponsorship for the Taitung Geng Yuan Cup National Junior and Youth Baseball Championships
4. Provided nutritional products to the Yilan Senior High School football team and Shunan Junior High School football team for many years
5. Provided long-standing support for instruments upgrades for the Dongshan Elementary School symphonic Band
6. Sponsored the Dongshan Township Sports Association's National Day Hiking Event
7. Provided nutritional products in support of the Dongshan Marathon, "Unique Double Reef" Marathon, Sanxing Annong River Marathon, and other sporting events.

Supports Local Community Activities

1. Provided long-term sponsorship for the Yilan Green Expo
2. Provided long-standing sponsorship for the International Children's Folklore & Folkgame Festival, Yilan
3. Signed a MOU with Yilan County Government to promote "Chiang Ku"
4. Provided buildings in the Jhong Leisure Agricultural Area of Dongshan Township for community use free of charge
5. Adopted and maintained a road in Renshan Botanical Garden, Yilan County.
6. Adopted and maintained the street lights of Zhongshan Village and Wanshan Village in Dongshan Township
7. Sponsored the Wanshan Historic Site Association
8. Sponsored various festival activities in the Zhongshan, Wanshan, and Babau Villiage of Dongshan Township

From Desert Herbal Wisdom to Scientific Validation

1. Classified as a top-grade medicinal herb in the Shennong Ben Cao Jing (Divine Farmer's Classic of Materia Medica), it is now endangered.
2. Sinphar's research into *Cistanche Tubulosa* began with an effort to preserve this rare and endangered desert botanical. Working alongside local farmers and botanists, Sinphar embarked on research into cultivation techniques for the plant.
3. In collaboration with a professor from Yale University, Sinphar introduced the patented plant fingerprinting technology Phytomics QC™. Through rigorous scientific analysis and quality standardization research, Sinphar further identified AIE2 as a key component in *Cistanche Tubulosa* associated with brain health, laying the foundation for subsequent research and development.





Q & A

